Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 4.5  

 
 

COMMON STOCK WARRANT    
    

        NEITHER
THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED
EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION. 

WARRANT TO PURCHASE 87,500 SHARES OF COMMON STOCK  

	No. CS-006	 	Dated: November 4, 2002

        THIS
CERTIFIES THAT, for value received, Oxford Finance Corporation, a Delaware Corporation ("Holder"), as successor in interest of the original holders of this warrant. Oxford Finance
Corporation, a Maryland corporation, is entitled to subscribe for and purchase EIGHTY SEVEN THOUSAND FIVE HUNDRED (87,500) shares of the fully paid and
nonassessable Common Stock ("the Shares") of BEYOND GENOMICS, INC., a DELAWARE corporation (the
"Company"), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the term "Common Stock" shall mean the
Company's presently authorized Common Stock, and any stock into which such Common Stock may hereafter be exchanged. 

        1.    Warrant Price.    The Warrant Price shall initially be ONE and  FIFTY/100
dollars ($1.50) per share, subject to adjustment as provided in Section 7 below. 

        2.    Conditions to Exercise.    The purchase right represented by this Warrant may be exercised at any time, or from
time to time, in whole or in part during the term commencing on the date hereof and ending on the earlier of: 

        (a)   5:00 P.M.
Eastern Standard time on the FIFTH annual anniversary of this Warrant Agreement; or 

        (b)   The
closing of the initial public offering of the Company's Common Stock pursuant to a registration statement under the Securities Act of 1933, as amended (the "Initial
Public Offering"). The Company shall provide notice of the Initial Public Offering to the Holder at least 30 days prior to the closing thereof; or 

        (c)   The
effective date of the merger of the Company with or into, the consolidation of the Company with, or the sale by the Company of all or substantially all of its assets
or all or substantially all of its shares to another corporation or other entity (other than such a transaction wherein the shareholders of the Company retain or obtain a majority of the voting
capital stock of the surviving, resulting, or purchasing corporation); provided that the Company shall notify the registered Holder of this Warrant of the proposed effective date of the merger,
consolidation, or sale at least 30 days prior to the effectiveness thereof. 

        In
the event that, although the Company shall have given notice of a transaction pursuant to subparagraph (b) or subparagraph (c) hereof, the transaction does not close
within 60 days of the day specified by the Company, unless otherwise elected by the Holder any exercise of the Warrant subsequent to the giving of such notice shall be rescinded and the Warrant
shall again be exercisable until terminated in accordance with this Paragraph 2. 

1

 

        3.    Method of Exercise; Payment: Issuance of Shares; Issuance of New Warrant.    

        (a)    Cash Exercise.    Subject to Section 2 hereof, the purchase right represented by this Warrant may be
exercised by the Holder hereof, in whole or in part, by the surrender of this Warrant (with a duly executed Notice of Exercise in the form attached hereto) at the principal office of the Company (as
set forth in Section 18 below) and by payment to the Company, by check, of an amount equal to the then applicable Warrant Price per share multiplied by the number of shares then being
purchased. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased shall be in the name of, and delivered to, the Holder hereof, or as
such Holder may direct (subject to the terms of transfer contained herein and upon payment by such Holder hereof of any applicable transfer taxes). Such delivery shall be made within 10 days
after exercise of the Warrant and at the Company's expense and, unless this Warrant has been fully exercised or expired, a new Warrant having terms and conditions substantially identical to this
Warrant and representing the portion of the Shares, if any, with respect to which this Warrant shall not have been exercised, shall also be issued to the Holder hereof within 10 days after
exercise of the Warrant. 

        (b)    Net Issue Exercise.    In lieu of exercising this Warrant pursuant to Section 3(a), Holder may elect to
receive shares equal to the value of this Warrant (or of any portion thereof remaining unexercised) by surrender of this Warrant at the principal office of the Company together with notice of such
election, in which event the Company shall issue to Holder the number of shares of the Company's Common Stock computed using the following formula: 

	 	X =	 	Y (A-B)
 A	 	 

Where
X = the number of shares of Common Stock to be issued to Holder. 

	Y
	=  the
number of shares of Common Stock purchasable under this Warrant (at the date of such calculation).

	A
	=  the
Fair Market Value of one share of the Company's Common Stock (at the date of such calculation).

	B
	=  Warrant
Price (as adjusted to the date of such calculation). 

        (c)    Fair Market Value.    For purposes of this Section 3, Fair Market Value of one share of the Company's
Common Stock shall mean: 

          (i)  In
the event of an exercise in connection with an Initial Public Offering, the per share Fair Market Value for the Common Stock shall be the Offering Price at which the
underwriters initially sell Common Stock to the public; or 

         (ii)  The
average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary, or the average of, the last
reported sale price of the Common Stock or the closing price quoted on the Nasdaq National Market System ("NMS") or on any exchange on which the Common Stock is listed, whichever is applicable, as
published in The Wall Street Journal over the ten (10) trading days prior to the date of determination of fair market value; or 

        (iii)  In
the event of an exercise in connection with a merger, acquisition or other consolidation in which the Company is not the surviving entity, as described in
Section 2(c), the per share Fair Market Value for the Common Stock shall be the value to be received per share of Common Stock by all holders of the Common Stock in such transaction as
determined by the Board of Directors; or 

2

 

        (iv)  If
the Common Stock is not publicly traded, the per share fair market value of the Common Stock shall be as determined in good faith by the Company's Board of Directors
unless Holder elects to have such fair market value determined by an appraiser, which election must be made by Holder within ten (10) business days of the date the Company notifies Holder of
the fair market value as determined by its Board of Directors. In the event of such an appraisal, the cost thereof shall be borne by the Holder unless such appraisal results in a fair market value in
excess of 115% of that determined by the Company's Board of Directors, in which event the Company shall bear the cost of such appraisal. 

        In
the event of 3(c)(iii) or 3(c)(iv), above, the Company's Board of Directors shall prepare a certificate, to be signed by an authorized Officer of the Company, setting forth in
reasonable detail the basis for and method of determination of the per share Fair Market Value of the Common Stock. The Board will also certify to the Holder that this per share Fair Market Value will
be applicable to all holders of the Company's Common Stock. Such certification must be made to Holder at least thirty (30) business days prior to the proposed effective date of the merger,
consolidation, sale, or other triggering event as defined in 3(c)(iii) and 3(c)(iv). 

        (d)    Automatic Exercise.    To the extent this Warrant is not previously exercised, it shall be automatically
exercised in accordance with Sections 3(b) and 3(c) hereof (even if not surrendered) immediately before: (i) its expiration, or (ii) the consummation of any consolidation or merger of
the Company, or any sale or transfer of a majority of the Company's assets or stock pursuant to Section 2(b) and 2(c). 

        4.    Representations and Warranties of Holder and Restrictions on Transfer Imposed by the Securities Act of 1993.    

        (a)    Representations and Warranties by Holder.    The Holder represents and warrants to the Company with respect to
this purchase as follows: 

          (i)  The
Holder has substantial experience in evaluating and investing in private placement transactions of securities of companies similar to the Company so that the Holder
is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its interests. 

         (ii)  The
Holder is acquiring the Warrant and the Shares of Common Stock issuable upon exercise of the Warrant (collectively the "Securities") for investment for its own
account and not with a view to, or for resale in connection with, any distribution thereof. The Holder understands that the Securities have not been registered under the Securities Act of 1933, as
amended (the "Act") by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide nature of the investment intent as expressed
herein. In this connection, the Holder understands that, in the view of the Securities and Exchange Commission (the "SEC"), the statutory basis for such exemption may be unavailable if this
representation was predicated solely upon a present intention to hold the Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or
decrease in the market price of the Securities or for a period of one year or any other fixed period in the future. 

        (iii)  The
Holder acknowledges that the Securities must be held indefinitely unless subsequently registered under the Act or an exemption from such registration is available.
The Holder is aware of the provisions of Rule 144 promulgated under the Act ("Rule 144") which permits limited resale of securities purchased in a private placement subject to the
satisfaction of certain conditions, including, in case the securities have been held for more than one but less than two years, the existence of a public market for the shares, the availability of
certain public information about the Company, the resale occurring not less than one years after a 

3

 

party
has purchased and paid for the security to be sold, the sale being through a "broker's transaction" or in a transaction directly with a "market maker" (as provided by Rule 144(f)) and the
number of shares or other securities being sold during any three-month period not exceeding specified limitations. 

        (iv)  The
Holder further understands that at the time the Holder wishes to sell the Securities there may be no public market upon which such a sale may be effected, and that
even if such a public market exists, the Company may not be satisfying the current public information requirements of Rule 144, and that in such event, the Holder may be precluded from selling
the Securities under Rule 144 unless a) a one-year minimum holding period has been satisfied and b) the Holder was not at the time of the sale nor at any time during
the three-month period prior to such sale an affiliate of the Company. 

         (v)  The
Holder has had an opportunity to discuss the Company's business, management and financial affairs with its management and an opportunity to review the Company's
facilities. The Holder understands that such discussions, as well as the written information issued by the Company, were intended to describe the aspects of the Company's business and prospects which
it believes to be material but were not necessarily a thorough or exhaustive description. 

        (b)    Legends.    Each certificate representing the Securities shall be endorsed with the following legend: 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED UNLESS COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, A "NO ACTION" LETTER FROM
THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES AND EXCHANGE COMMISSION, OR (IF REASONABLY REQUIRED BY THE
COMPANY) AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

        The
Company need not enter into its stock register a transfer of Securities unless the conditions specified in the foregoing legend are satisfied. The Company may also instruct its
transfer agent not to
register the transfer of any of the Shares unless the conditions specified in the foregoing legend are satisfied. 

        (c)    Removal of Legend and Transfer Restrictions.    The legend relating to the Act endorsed on a certificate
pursuant to paragraph 4(b) of this Warrant and the stop transfer instructions with respect to the Securities represented by such certificate shall be removed and the Company shall issue a
certificate without such legend to the Holder of the Securities if (i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10 of the Act is
available or (ii) the Holder provides to the Company an opinion of counsel for the Holder reasonably satisfactory to the Company, or a no-action letter or interpretive opinion of
the staff of the SEC reasonably satisfactory to the Company, to the effect that public sale, transfer or assignment of the Securities may be, to the effect that public sale, transfer or assignment of
the Securities may be made without registration and without compliance with any restriction such as Rule 144. 

        5.    Condition of Transfer or Exercise of Warrant.    It shall be a condition to any transfer or exercise of this
Warrant that at the time of such transfer or exercise, the Holder shall provide the Company with a representation in writing that the Holder or transferee is acquiring this Warrant and the shares of
Common Stock to be issued upon exercise, for investment purposes only and not with a view to any 

4

 

sale
or distribution, or will provide the Company with a statement of pertinent facts covering any proposed distribution. As a further condition to any transfer of this Warrant or any or all of the
shares of Common Stock issuable upon exercise of this Warrant, other than a transfer registered under the Act, the Company must have received a legal opinion, in form and substance satisfactory to the
Company and its counsel, reciting the pertinent circumstances surrounding the proposed transfer and stating that such transfer is exempt from the registration and prospectus delivery requirements of
the Act. Each certificate evidencing the shares issued upon exercise of the Warrant or upon any transfer of the shares (other than a transfer registered under the Act or any subsequent transfer of
shares so registered) shall, at the Company's option, contain a legend in form and substance satisfactory to the Company and its counsel, restricting the transfer of the shares to sales or other
dispositions exempt from the requirements of the Act. 

        As
further condition to each transfer, the Holder shall surrender this Warrant to the Company and the transferee shall receive and accept a Warrant, of like tenor and date, executed by
the Company. 

        6.    Stock Fully Paid; Reservation of Shares.    All Shares, which may be issued upon the exercise of the rights
represented by this Warrant, will, upon issuance, be fully paid and nonassessable, and free from all taxes, liens, and charges with respect to the issue thereof. During the period within which the
rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for issuance upon exercise of the purchase rights evidenced by this Warrant, a
sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. 

        7.    Adjustment for Certain Events.    In the event of changes in the outstanding Common Stock by reason of stock
dividends, split-ups, recapitalizations, reclassifications, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the
number and class of shares available under the Warrant in the aggregate and the Warrant Price shall be correspondingly adjusted, as appropriate, by the Board of Directors of the Company. The
adjustment shall be such as will give the Holder of this Warrant upon exercise for the same aggregate Warrant Price the total number, class and kind of shares as he would have owned had the Warrant
been exercised prior to the event and had he continued to hold such shares until after the event requiring adjustment. 

        8.    Notice of Adjustments.    Whenever any Warrant Price shall be adjusted pursuant to Section 7 hereof, the
Company shall prepare a certificate signed by an officer of the Company's chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment,
the method by which such adjustment was calculated, and the Warrant Price and number of shares issuable upon exercise of the Warrant after giving effect to such adjustment, and shall cause copies of
such certificate to be mailed (by certified or registered mail, return receipt required, postage prepaid) within thirty (30) days of such adjustment to the Holder of this Warrant as set forth
in Section 18 hereof. 

        9.    "Market Stand-Off" Agreement.    Holder hereby agrees that for a period of up to 180 days
following the effective date of the first registration statement of the Company covering common stock (or other securities) to be sold on its behalf of the Company in an underwritten public offering,
it will not, to the extent requested by the Company and any underwriter, sell or otherwise transfer or dispose of (other than to donees or transferees who agree to be similarly bound) any of the
Shares at any time during such period except common stock included in such registration; provided, however, that all officers and directors of the Company who hold securities of the Company or options
to acquire securities of the Company and all other persons with registration rights enter into similar agreements. 

        10.    Transferability of Warrant.    This Warrant is transferable on the books of the Company at its principal office
by the registered Holder hereof upon surrender of this Warrant properly endorsed, subject to compliance with Section 5 and applicable federal and state securities laws. The Company 

5

 

shall
issue and deliver to the transferee a new Warrant representing the Warrant so transferred. Upon any partial transfer, the Company will issue and deliver to Holder a new Warrant with respect to
the Warrant not so transferred. Holder shall not have any right to transfer any portion of this Warrant to any direct competitor of the Company. 

        11.    No Fractional Shares.    No fractional share of Common Stock will be issued in connection with any exercise
hereunder, but in lieu of such fractional share the Company shall make a cash payment therefor upon the basis of the Warrant Price then in effect. 

        12.    Charges, Taxes and Expenses.    Issuance of certificates for shares of Common Stock upon the exercise of this
Warrant shall be made without charge to the Holder for any United States or state of the United States documentary stamp tax or other incidental expense within respect to the issuance of such
certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder. 

        13.    No Shareholder Rights Until Exercise.    This Warrant does not entitle the Holder hereof to any voting rights
or other rights as a shareholder of the Company prior to the exercise hereof. 

        14.    Registry of Warrant.    The Company shall maintain a registry showing the name and address of the registered
Holder of this Warrant. This Warrant may be surrendered for exchange or exercise, in accordance with its terms, at such office or agency of the Company, and the Company and Holder shall be entitled to
rely in all respects, prior to written notice to the contrary, upon such registry. 

        15.    Loss, Theft, Destruction or Mutilation of Warrant.    Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to it, and, if mutilated, upon
surrender and cancellation of this Warrant, the Company will execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof. 

        16.    Miscellaneous.    

        (a)    Issue Date.    The provisions of this Warrant shall be construed and shall be given effect in all respect as if
it had been issued and delivered by the Company on the date hereof. 

        (b)    Successors.    This Warrant shall be binding upon any successors or assigns of the Company. 

        (c)    Governing Law.    This Warrant shall be governed by and construed in accordance with the laws of the
Commonwealth of Virginia. 

        (d)    Headings.    The headings used in this Warrant are used for convenience only and are not to be considered in
construing or interpreting this Warrant. 

        (e)    Saturdays, Sundays, Holidays.    If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall be a Saturday or a Sunday or shall be a legal
holiday in the Commonwealth of Virginia, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday. 

        17.    No Impairment.    The Company will not, by amendment of its Articles of Incorporation or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of
all such action as may be necessary or appropriate in order to protect the rights of the Holder hereof against impairment. 

        18.    Addresses.    Any notice required or permitted hereunder shall be in writing and shall be mailed by overnight
courier, registered or certified mail, return receipt required, and postage pre-paid, 

6

 

or
otherwise delivered by hand or by messenger, addressed as set forth below, or at such other address as the Company or the Holder hereof shall have furnished to the other party. 

	 	 	If to the Company:	 	BEYOND GENOMICS, INC.

40 BEAR HILL ROAD

WALTHAM, MA 02451

Attn: BRIAN ST. JEAN	 	 
	

 	
 	

If to the Holder:	
 	

Oxford Finance Corporation, a Delaware Corporation

133 N. Fairfax Street

Alexandria, VA 22314

Attn: J. Alden Philbrick	
 	

 

7

 

        IN
WITNESS WHEREOF, BEYOND GENOMICS, INC. has caused this Warrant (a transferred warrant as set forth in the first paragraph
hereto) to be executed by its officers thereunto duly authorized. 

Dated
as of August 9, 2004. 

	By:	 	/s/  BRIAN ST. JEAN      
	 	 
	Name:	 	BRIAN ST. JEAN
	 	 
	Title:	 	VICE PRESIDENT, FINANCE
	 	 

8

   NOTICE OF EXERCISE  

	TO:
	BEYOND GENOMICS, INC.

40 BEAR HILL ROAD

WALTHAM, MA 02451  

         1.     The undersigned, Oxford Finance Corporation, a Delaware corporation ("Holder") elects to acquire shares of the Common Stock of BEYOND
GENOMICS, INC. (the "Company"), pursuant to the terms of the Stock Purchase Warrant dated November 4, 2002, (the "Warrant"). 

        2.     The
Holder exercises its rights under the Warrant as set forth below: 

	o
	The
Holder elects to purchase 87,500 shares of Common Stock as provided in
Section 3(a), (c) and tenders herewith a check in the amount of $131,250 as payment of the purchase price.

	o
	The
Holder elects to convert the purchase rights into shares of Common Stock as provided in Section 3(b), (c) of the Warrant. 

        3.     The
Holder surrenders the Warrant with this Notice of Exercise. 

        4.     The
Holder represents that it is acquiring the aforesaid shares of Common Stock for investment and not with a view to or for resale in connection with, distribution and
that the Holder has no present intention of distributing or reselling the shares. 

        5.     Please
issue a certificate representing the shares of Common Stock in the name of the Holder or in such other name as is specified below: 

	

Name:	

 	
 	

 
	 	
	 	 
	

Address:	

 	
 	

 
	 	
	 	 
	

Taxpayer I.D.:	

 	
 	

 
	 	
	 	 
	

 	

Oxford Finance Corporation, a Delaware Corporation	
 	

 
	

By:	

 	
 	

 
	 	
	 	 
	

Name:	

 	
 	

 
	 	
	 	 
	

Title:	

 	
 	

 
	 	
	 	 
	

Date:	

 	
 	

 
	 	
	 	 

9

QuickLinks

COMMON STOCK WARRANTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.6    
    

 
 

FORM OF COMMON STOCK WARRANT    
    

        THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"SECURITIES ACT"), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT
WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR "BLUE SKY" LAWS. 

	No. CS-[    ]	 	Warrant to Purchase Shares of

Common Stock

WARRANT
TO PURCHASE 

COMMON
STOCK 

OF

BG
MEDICINE, INC. 

(A
DELAWARE CORPORATION) 

        BG
Medicine, Inc., a Delaware corporation (the "Company"), for value received, hereby certifies
that                        or its
registered assigns (the "Holder"), is entitled, subject to the terms set forth below, to purchase from the Company, at any time before 5:00 p.m.,
EST, on [10 years from Issue Date] (the "Expiration Date"), the amount of
Common Stock, par value $0.001 per share (the "Common Stock"), determined pursuant to Section 1 herein at a purchase price per share determined
pursuant to Section 2 herein. 

        This
Warrant is issued pursuant to that certain Securities Purchase Agreement dated as of September 1, 2005 between the Company and the Purchasers (as defined therein) (the
"Purchase Agreement"), and is entitled to the benefits of the Purchase Agreement. The terms of all warrants issued pursuant to the Purchase Agreement
(including this Warrant) are and will be identical except as to the name of the holder thereof, the amount of Common Stock to be purchased by such holder and the date of issuance thereof. Except as to
those terms otherwise defined in this Warrant, all capitalized terms used in this Warrant shall have the respective meanings ascribed to them in the Purchase Agreement. 

        1.    Number of Shares for Which Warrant is Exercisable.    

        1.1    Upon
the consummation of a Qualified Financing prior to the Due Date, the Warrant shall be exercisable for the number of shares of Common Stock determined by dividing
(A) the original principal amount of the Note held by the Holder by (B) the price per share paid by the investors for the class and series of equity securities issued and sold in the
Qualified Financing, as adjusted pursuant to the terms of Section 4 herein, and then multiplying the quotient obtained thereby by thirty percent (30%). 

        1.2    Notwithstanding
anything contained herein to the contrary, if for any reason a Qualified Financing is not consummated prior to the Due Date, the Warrant may, at the sole
discretion of the Holder, be exercisable for the number of shares of Common Stock determined (i) pursuant to Section 1.1 above if and when a Qualified Financing is consummated, or
(ii) by dividing (A) the then outstanding principal balance of the Note held by such Holder, by (B) $1.50, as adjusted 

 

pursuant
to the terms of Section 4 herein, and then multiplying the quotient obtained thereby by thirty percent (30%). 

        1.3    Notwithstanding
anything contained herein to the contrary, upon the consummation of a Liquidation Event prior to the consummation of a Qualified Financing, the Warrant
may, at the sole discretion of the Holder, be exercisable for the number of shares of Common Stock determined (i) pursuant to Section 1.1 above if and when a Qualified Financing is
consummated, or (ii) by dividing (A) the then outstanding principal balance of the Note held by such Holder, by (B) $1.50, as adjusted pursuant to the terms of Section 4
herein, and then multiplying the quotient obtained thereby by thirty percent (30%). 

        2.    The Exercise Price.    The price per share of Common Stock at which this Warrant may be exercised (the
"Exercise Price") shall be $0.01. 

        3.    Exercise.    

        3.1    Manner of Exercise; Payment in Cash.    This Warrant may be exercised by the Holder, in whole or in part, by
surrendering this Warrant, with the purchase form appended hereto as Exhibit A duly executed by the Holder, at the principal office of the
Company, or at such other place as the Company may designate, accompanied by payment in full of the Exercise Price payable in respect of the number of shares of Common Stock purchased upon such
exercise. Payment of the Exercise Price shall be in cash or by certified or official bank check payable to the order of the Company. 

        3.2    Effectiveness.    Each exercise of this Warrant shall be deemed to have been effected immediately prior to the
close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 3.1 above. At such time, the person or persons in whose name or names any
certificates for Common Stock (or other securities to be issued hereunder) shall be issuable upon such exercise as provided in Section 3.3 below shall be deemed to have become the holder or
holders of record of the Common Stock represented by such certificates. 

        3.3.    Delivery of Certificates.    As soon as practicable after the exercise of this Warrant in full or in part, and
in any event within ten business days thereafter, the Company at its sole expense will cause to be issued in the name of, and delivered to, the Holder, or, subject to the terms and conditions hereof,
as such Holder may direct: 

        (a)   A
certificate or certificates for the number of full shares of Common Stock to which such Holder shall be entitled upon such exercise plus, in lieu of any fractional
share to which such Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3.4 hereof, and 

        (b)   In
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the
number of shares of Common Stock (without giving effect to any adjustment therein) equal to the number of such shares called for on the face of this Warrant minus the number of such shares purchased
by the Holder upon such exercise as provided in Section 3.1 above. 

        3.4.    Fractional Shares.    The Company shall not be required upon the exercise of this Warrant to issue any
fractional shares, but shall make an adjustment therefor in cash on the basis of the fair market value of the Common Stock determined pursuant to Section 3.5(c) herein. 

        3.5    Right to Convert Warrant into Stock: Net Issuance.    

        (a)    Right to Convert.    In addition to and without limiting the rights of the Holder under the terms of this
Warrant, the Holder shall have the right to convert this Warrant or any portion 

2

 

thereof
(the "Conversion Right") into shares of Common Stock as provided in this Section 3.5. Upon exercise of the Conversion Right with respect
to a particular number of shares subject to this Warrant (the "Converted Warrant Shares"), the Company shall deliver to the Holder (without payment by
the Holder of any Exercise Price or any cash or other consideration) that number of shares of fully paid and nonassessable Common Stock equal to the quotient obtained by dividing (X) the value
of this Warrant (or the specified portion hereof) on the Conversion Date (as defined in subsection (b) hereof), which value shall be determined by subtracting (A) the aggregate Exercise
Price of the Converted Warrant Shares immediately prior to the exercise of the Conversion Right from (B) the aggregate fair market value of the Converted Warrant Shares issuable upon exercise
of this Warrant (or the specified portion hereof) on the Conversion Date by (Y) the fair market value of one share of Common Stock on the Conversion Date. 

        Expressed
as a formula, such conversion shall be computed as follows: 

	N	 	=	 	B-A
 Y
	 	 	 	 	 

	where:	 	N	 	=	 	the number of shares of Common Stock that may be issued to Holder
	

 	
 	

Y	
 	

=	
 	

the fair market value (FMV) of one share of Common Stock
	

 	
 	

A	
 	

=	
 	

the aggregate Warrant Price (Converted Warrant Shares × Exercise Price)
	

 	
 	

B	
 	

=	
 	

the aggregate FMV (i.e., FMV × Converted Warrant Shares)

        No
fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than
a whole number, the Company shall pay to the Holder an amount in cash equal to the fair market value of the resulting fractional share of the Conversion Date. 

        (b)    Method of Exercise.    The Conversion Right may be exercised by the Holder by the surrender of this Warrant at
the principal office of the Company together with the Subscription Form in the form attached hereto duly completed and executed and indicating the number of shares subject to this Warrant which are
being surrendered (referred to in Section 3.5(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of
this Warrant together with the aforesaid written statement, or on such later date as is
specified therein (the "Conversion Date"), and, at the election of the Holder hereof, may be made contingent upon the occurrence of any of the events
specified in Section 4. Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new Warrant evidencing the balance of the shares remaining subject to
this Warrant, shall be issued as of the Conversion Date and shall be delivered to the Holder within 30 days following the Conversion Date. 

        (c)    Determination of Fair Market Value.    For purposes of this Section 3.5, "fair market value" of a share
of Common Stock as of a particular date (the "Determination Date") shall mean: 

          (i)  If
the Conversion Right is exercised in connection with and contingent upon a public offering, and if the Company's Registration Statement relating to such public
offering ("Registration Statement") has been declared effective by the Securities and Exchange Commission, then the initial "Price to Public" specified
in the final prospectus with respect to such offering. 

3

 

         (ii)  If
the Conversion Right is not exercised in connection with and contingent upon a public offering, then as follows: 

	(1)
	If
traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock on such exchange over the
five-day period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common Stock has been traded on such exchange;

	(2)
	If
traded over-the-counter, the fair market value of the Common Stock shall be deemed to be the average of the closing bid prices of the Common Stock over the
five-day period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common Stock has been traded over-the-counter; and

	(3)
	If
there is no public market for the Common Stock, then fair market value shall be determined in good faith by the Board of Directors of the Company. 

        4.    Certain Adjustments.    

        4.1    Changes in Common Stock.    If the Company shall (i) combine the outstanding shares of Common Stock into
a lesser number of shares, (ii) subdivide the outstanding shares of Common Stock into a greater number of shares, or (iii) issue additional shares of Common Stock as a dividend or other
distribution with respect to the Common Stock, the number of shares of Common Stock to be issued pursuant to the terms of the Warrant shall be equal to the number of shares which the Holder would have
been entitled to receive after the happening of any of the events described above if such shares had been issued immediately prior to the happening of such event, such adjustment to become effective
concurrently with the effectiveness of such event. The Exercise Price in effect immediately prior to any such combination of Common Stock shall, upon the effectiveness of such combination, be
proportionately increased. The Exercise Price in effect immediately prior to any such subdivision of Common Stock or at the record date of such dividend shall upon the effectiveness of such
subdivision or immediately after the record date of such dividend be proportionately reduced. 

        4.2    Reorganizations and Reclassifications.    If there shall occur any capital reorganization or reclassification
of the Common Stock (other than a change in par value or a subdivision or combination as provided for in Section 4.1), then, as part of any such reorganization or reclassification, lawful
provision shall be made so that the Holder shall have the right thereafter to receive upon the exercise hereof the kind and amount of shares of stock or other securities or property which such Holder
would have been entitled to receive if, immediately prior to any such reorganization or reclassification, such Holder had held the number of shares of Common Stock which were then purchasable upon the
exercise of this Warrant. In any such case, appropriate adjustment (as reasonably determined by the Board of Directors of the Company) shall be made in the application of the provisions set forth
herein with respect to the rights and interests thereafter of the Holder such that the provisions set forth in this Section 4 (including provisions with respect to adjustment of the Exercise
Price) shall thereafter be applicable, as nearly as is reasonably practicable, in relation to any shares of stock or other securities or property thereafter deliverable upon the exercise of this
Warrant. 

        4.3    Merger, Consolidation or Sale of Assets.    Subject to the provisions of this Section 4, if there shall
be a merger or consolidation of the Company with or into another corporation (other than a merger or reorganization involving only a change in the state of incorporation of the Company or the
acquisition by the Company of other businesses where the Company survives as a going concern), or the sale of all or substantially all of the Company's capital stock or assets to any other person,
then as a part of such transaction, provision shall be made so that the Holder shall 

4

 

thereafter
be entitled to receive the number of shares of stock or other securities or property of the Company, or of the successor corporation resulting from the merger, consolidation or sale, to
which the Holder would have been entitled if the Holder had exercised its rights pursuant to the Warrant immediately prior thereto. In any such case, appropriate adjustment shall be made in the
application of the provisions of this Section 4 to the end that the provisions of this Section 4 shall be applicable after that event in as nearly equivalent a manner as may be
practicable. 

        4.4    Statement of Adjustment.    Whenever the Exercise Price or the Common Stock to be issued hereunder shall be
adjusted as provided in this Section 4, the Company shall forthwith file with the Secretary of the Company or at such other place as shall be designated by the Company, a statement, signed by
its chief financial officer, showing in detail the facts requiring such adjustment, the Exercise Price in effect before and after such adjustment and the kind and amount of shares of capital stock,
securities or other property thereafter to be received upon the exercise of this Warrant. The Company shall also cause a copy of such statement to be sent in the manner specified in
Section 8.02 of the Purchase Agreement to the Holder. Where appropriate, such copy may be given in advance and may be included as part of a notice required to be mailed under the provisions of
Section 4.5. 

        4.5    Notice of Adjustment.    In the event the Company shall propose to take any action of the types described in
Sections 4.1, 4.2 or 4.3, the Company shall give notice to the Holder in the manner set forth in Section 8.02 of the Purchase Agreement, which notice shall specify the record date, if any, with
respect to any such action and the date on which such action is to take place. Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect
of such action (to the extent such effect may be known at the date of such notice) on the Exercise Price and the number, kind or class of shares or other securities or property which shall be
deliverable or purchasable upon the occurrence of such action or deliverable upon the exercise hereof. In the case of any action which would require the fixing of a record date, such notice shall be
given at least ten days prior to the date so fixed, and in case of all other actions, such notice shall be given at least 20 days prior to the taking of such proposed action. 

        4.6    Taxes.    The Company shall pay all documentary, stamp or other transactional taxes, but excluding any income
or withholding taxes, attributable to the issuance or delivery of shares of capital stock of the Company upon the exercise or conversion of this Warrant. 

        5.    Reservation of Stock.    The Company will at all times reserve and keep available, solely for issuance and
delivery upon the exercise of this Warrant, such shares of Common Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. The Company
covenants that all shares of Common Stock so issuable will, when issued, be duly and validly issued and fully paid and nonassessable. 

        6.    Replacement of Warrants.    Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably
satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 

        7.    Transferability.    Subject to compliance with applicable federal and state securities laws, this Warrant and
all rights hereunder are transferable in whole or in part by the Holder to any person or entity upon written notice to the Company. The transfer shall be recorded on the books of the Company upon the
surrender of this Warrant, properly endorsed, to the Company at its principal offices, and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. In
the event of a partial transfer, the Company shall issue to the holders one or more appropriate new warrants. 

5

 

        8.    No Impairment.    The Company will not, by amendment of its Second Amended and Restated Certificate of
Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, or any other similar voluntary action, avoid or seek to avoid the observance or performance of any
of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the holder of the Warrant against impairment due to such event. Without limiting the generality of the foregoing, the Company (a) will not increase the value assigned to
any shares of stock receivable on the exercise of the Warrant above the amount payable therefor on such exercise, (b) will take all action that may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of stock, free from all taxes, liens and charges with respect to the issue thereof, on the exercise of all of the Warrants
from time to time outstanding, and (c) will not consolidate with or merge into any other person or permit any such person to consolidate with or merge into the Company (if the Company is not
the surviving person), unless such other person shall expressly assume in writing and will be bound by all the terms of this Warrant. 

        9.    Notices.    All notices, requests and other communications hereunder shall be made pursuant to the provisions of
Section 9.04 of the Purchase Agreement. 

        10.    Waivers and Modifications.    Any term or provision of this Warrant may be amended, modified or waived with the
written consent of the Company and the Purchasers holding Warrants with at least 75% of the amounts then outstanding under all of the Warrants. 

        11.    Headings.    The headings in this Warrant are for convenience of reference only and shall in no way modify or
affect the meaning or construction of any of the terms or provisions of this Warrant. 

        12.    Governing Law.    This Warrant will be governed by and construed in accordance with and governed by the laws of
State of Delaware, without giving effect to the conflict of law principles thereof. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

6

 

        IN
WITNESS WHEREOF, BG Medicine, Inc. caused this Warrant to be executed by an officer thereunto duly authorized. 

	 	 	BG MEDICINE, INC.
	

 	
 	

By:	

 
	 	 	 	
 Name: Pieter Muntendam, M.D.

Title: President

7

EXHIBIT A  

PURCHASE FORM  

To: BG MEDICINE, INC. 

        The
undersigned pursuant to the provisions set forth in the attached Warrant (No. W-            ), hereby irrevocably elects to (check
one): 

	o
	(A)
purchase              shares of the Common Stock, par value $0.001 per share, of BG
Medicine, Inc. (the "Common Stock"), covered by such Warrant and herewith makes payment of $            ,
representing the full purchase price for such shares at the price per share provided for in such Warrant; or

	o
	(B)
convert              Converted Warrant Shares into that number of shares of fully paid and
nonassessable shares of Common Stock, determined pursuant to the provisions of Section 3.5 of the Warrant. 

The Common Stock for which the Warrant may be exercised or converted shall be known herein as the "Warrant Stock". 

        The
undersigned is aware that the Warrant Stock has not been and will not be registered under the Securities Act of 1933, as amended (the "Securities
Act") or any state securities laws. The undersigned understands that reliance by the Company on exemptions under the Securities Act is predicated in part upon the truth and
accuracy of the statements of the undersigned in this Purchase Form. 

        The
undersigned represents and warrants that (1) it has been furnished with all information which it deems necessary to evaluate the merits and risks of the purchase of the
Warrant Stock, (2) it has had the opportunity to ask questions concerning the Warrant Stock and the Company and all questions posed have been answered to its satisfaction, (3) it has
been given the opportunity to obtain any additional information it deems necessary to verify the accuracy of any information obtained concerning the Warrant Stock and the Company and (4) it has
such knowledge and experience in financial and
business matters that it is able to evaluate the merits and risks of purchasing the Warrant Stock and to make an informed investment decision relating thereto. 

        The
undersigned hereby represents and warrant that it is purchasing the Warrant Stock for its own account for investment and not with a view to the sale or distribution of all or any
part of the Warrant Stock. 

        The
undersigned understands that because the Warrant Stock has not been registered under the Securities Act, it must continue to bear the economic risk of the investment for an
indefinite period of time and the Warrant Stock cannot be sold unless it is subsequently registered under applicable federal and state securities laws or an exemption from such registration is
available. 

        The
undersigned agrees that it will in no event sell or distribute or otherwise dispose of all or any part of the Warrant Stock unless (1) there is an effective registration
statement under the Securities Act and applicable state securities laws covering any such transaction involving the Warrant Stock, or (2) the Company receives an opinion satisfactory to the
Company of the undersigned's legal counsel stating that such transaction is exempt from registration. The undersigned consents to the placing of a legend on its certificate for the Warrant Stock
stating that the Warrant Stock has not been registered and setting forth the restriction on transfer contemplated hereby and to the placing of a stop transfer order on the books of the Company and
with any transfer agents against the Warrant Stock until the Warrant Stock may be legally resold or distributed without restriction. 

 

        The
undersigned has considered the federal and state income tax implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Stock. 

	 	 	

	 	 	 	 	 
	 	 	Dated:	 	 
	 	 	 	 	

2

 
Schedule of Warrant Holders  

AGTC
Advisors Fund, L.P.

Applied Genomic Technology Capital Fund, L. P.

Gilde Europe Food & Agribusiness Fund, B.V.

NewcoGen—Elan LLC

NewcoGen—Long Reign Holding LLC

NewcoGen—PE LLC

NewcoGen Equity Investors LLC

Pieter Muntendam

ST NewcoGen LLC

Stelios Papadopoulos 

3

QuickLinks

Exhibit 4.6

FORM OF COMMON STOCK WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]